Close Menu

NEW YORK – Immune mapping firm Serimmune has put the bulk of its previous research efforts on hold and shifted focus to aiding development of tests and vaccines for SARS-CoV-2.

The Goleta, California-based company combines next-generation sequencing with massive random peptide libraries to profile patient immune responses as part of research into diagnostic and therapeutic development for a variety of conditions including autoimmune diseases, cancers, and infectious disease.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A 50-year-old cold case was cracked using genetic genealogy, the New York Times reports.

NPR reports that some insect pests are now becoming resistant to Bt crops.

Science reports the US Food and Drug Administration did not consult an outside panel in its approval of remdesivir as a COVID-19 treatment.

In Nature this week: a framework for future human genomic research, PORE-cupine approach to study RNA structure using nanopore sequencing, and more.

Nov
10
Sponsored by
LGC

The COVID-19 pandemic created a paradigm shift in modern healthcare, where regulations, protocols, and mindsets had to be reworked in just a matter of months to keep up with the pace of the virus.